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                                                                      Abstract                                                                                                                                  
Problem: Human Papillomavirus (HPV) is a common sexually transmitted infection that will 
affect over 80% of sexually active men and women in their lifetime. HPV is the primary cause of 
cervical cancer in women and is linked to oropharyngeal and anal cancers in both men and 
women.  The HPV vaccine can be given as early as 11 years of age to both boys and girls. If 
administered before exposure to the virus, the vaccine can protect against the cancer-causing 
strains of HPV.  Despite this cancer prevention, there remains a low rate of HPV vaccine 
coverage among adolescents across the U.S.                   
Project Aim: The aim of this quality improvement project is to implement a standardized 
process for identifying patients in need of the vaccine and providing consistent recommendation 
for vaccination in a rural primary health care clinic.                     
Project Method: The project was implemented in a rural Kansas family practice clinic.  Lewin’s 
theory of change and three-step change model was be used as a theoretical framework to guide 
the implementation of this project.  The project began with a discussion with clinic providers and 
staff on barriers and current practices for identifying and recommending HPV vaccination.  A 
process map for identification was created utilizing staff input.  An educational in-service was 
provided to educate on the new process for identification of eligible patients, updated HPV-
related information, and strategies for recommendation practices.  After education, the 
identification and recommendation standardized process was followed and tracked for 
approximately 4 weeks.             
Results/Conclusion: Themes were identified and evaluated based on feedback from clinic staff 
and a process map was created for the clinic as a standardized process for practice change.  
Overall, 44 patients were identified as age-eligible to receive recommendation for the HPV 
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vaccine. Over half of these patient encounters were for acute or sick visits. These patients would 
have otherwise been missed opportunities prior to the clinic practice change.  Although there was 
no impact on vaccine administration rates observed, the results support standardized processes to 
screen eligible patients at every visit as an effective way for improving identification and 
recommendation for age-eligible patients in need of the HPV vaccine. 
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Establishing a Standardized Process to Improve Identification and Recommendation Practices of 
Patients Eligible to Receive the HPV Vaccine Series in a Rural Primary Care Clinic 
Human papillomavirus (HPV) is a common sexually transmitted infection that can cause 
different types of cancers in both men and women.  According to the Center for Disease Control 
and Prevention (CDC, 2018a), there are nearly 14 million new HPV infections that occur each 
year in the United States.  The HPV vaccine is comprised of a two-dose or three-dose series, 
depending on a person’s age at the time of initiation.  The CDC (2018b) recommends the vaccine 
for boys and girls age 11 or 12 years old but can be given as early as age 9.  It is the only 
vaccination that provides the opportunity to reduce the risk of HPV-related cancers, but the 
vaccine series must be completed before becoming sexually active to provide full protection.  
Barriers to vaccination that have been identified may include cost, access, lack of education, 
concerns about vaccine safety, as well as negative connotation with sexual activity (Cole, 
Thomas, Straup & Savage, 2017). 
Since the introduction of the HPV vaccine, there has been a 64% decrease in the 
prevalence of the cancer-causing types of HPV infection among girls age 14-19 (Markowitz et 
al., 2017). Despite this evidence supporting the significant impact on public health, there remains 
a low level of vaccine coverage both in the state of Kansas and nationally.  Efforts should be 
undertaken to increase HPV vaccine coverage to meet the goals set by The Department of Health 
and Human Services (2018). The Healthy People initiative aims to increase the rate of HPV 
vaccinations among adolescents to 80% by the year 2020.  By increasing provider knowledge 
and standardizing the delivery of HPV vaccine information, there is high potential for increasing 
parental knowledge and therefore impacting vaccination rates. 
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Statement of Problem 
Unfortunately, there remains a low-level of vaccination coverage among adolescents 
nation-wide, with only an estimated 53% of girls and 44% of boys age 13 to 17 years receiving 
the full two- or three-dose HPV vaccine series based on a national survey (Walker et al., 2018). 
Based on this same survey of adolescents, in the state of Kansas only 34% of adolescents are up 
to date on the vaccine (Walker et al., 2018). In 2014, most rural counties in Kansas had less than 
29% vaccine coverage among adolescents receiving the completed three-dose vaccine series 
(Immunize Kansas Coalition, 2014). 
Patient-provider interactions and conversations at initiation of the HPV vaccine is 
imperative in influencing decisions to increase HPV vaccine uptake (Clark, Cowan, Filipp, 
Fisher, & Stokley, 2016). With primary care clinics as a common area for these conversations to 
take place, there is opportunity to improve HPV-related conversations with adolescents, parents, 
and young adults by increasing provider knowledge.  In addition, the CDC (2018c) recommends 
implementing systems and/or clinic policies to decrease missed opportunities to vaccinate. These 
systems include creating a systematic process for checking immunization status and 
recommending the vaccine at every patient visit (CDC, 2018c). 
Providing standardized HPV vaccine information and recommendation for eligible 
patients and parents during all types of patient encounters can help to overcome barriers, address 
patient and parental knowledge gaps, and increase vaccine rates (Bernstein & Bocchini, 2017). 
Provider recommendation practices should focus on (a) highlighting that HPV vaccine prevents 
cancer, (b) reviewing the HPV vaccine dosing schedule, (c) emphasizing to not delay the vaccine 
until sexually active, (d) point out that HPV vaccine is part of recommended routine 
immunizations for males and females, (e) reviewing the safety profile of the HPV vaccine, and 
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finally, (f) the provider should be prepared to clarify parental concerns of the vaccine promoting 
sexual promiscuity (Bernstein & Bocchini, 2017). In a retrospective study reviewing the 
electronic medical record of male and female adolescents age 11-18 years old from 2006-2011, 
82% of visits were identified as missed opportunities for an eligible patient to receive the first 
dose of the HPV vaccine (Wong, Taylor, Wright, Opel & Katzenellenbogen, 2013). There were 
94% missed opportunities for the first does of the HPV vaccine identified for sick or non-
preventive type of visits compared to 61% missed opportunities for preventive visits (Wong et 
al., 2013). The findings of this study display that all clinical encounters for patients age-eligible 
to receive the HPV vaccine should be viewed as potential opportunities to provide HPV 
vaccination recommendation (Wong et al., 2013).  
In 2017, the state of Kansas was among the lowest ranking group of 12 other states that 
had a greater than one dose of HPV vaccine coverage rate less than 60% (Walker et al., 2018). In 
addition, as of 2017 there was an 11% lower rate of adolescents who received the first does of 
the HPV vaccine in rural areas compared to urban areas (CDC, 2018d). The aim of this project 
was to improve identification and recommendation practices of male and female patients age 11 
to 26 years in need of the HPV vaccine for all visit types in a rural primary care clinic by 
creating a standardized process to identify patients eligible to receive the vaccine and provide 
consistent recommendation.  
Background and Significance 
History of HPV Vaccine  
 The HPV vaccine was first introduced to several countries in 2006 as a quadrivalent 
vaccine in a three-dose series (Cutts et al., 2007). In 2016, the CDC began recommending the 
two-dose series if given to patients before their 15th birthday. Quadrivalent HPV vaccines protect 
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against high-risk genotypes 16 and 18, as well as low-risk genotypes 6 and 1.  There is also a 9-
valent HPV vaccine, which was introduced in 2014, and targets the 4 original genotypes and five 
additional HPV genotypes (Meites, Kempe, & Markowitz, 2016). The United States currently 
only distributes the 9-valent HPV vaccine (Meites, Kempe, & Markowitz, 2016). The high-risk 
HPV types 16 and 18 have been linked to certain cancers and are targeted in all the HPV vaccine 
types and HPV types 16 and 18 are linked to approximately 70% of all cervical cancers (Castle 
and Maza, 2016). It is estimated that cervical cancer is the cause of 91% of HPV-related deaths 
globally (Cutts et al., 2007). According to the CDC (2018b), the vaccine can be given as early as 
age 9, but it should be recommended to start the series at age 11 or 12 years.  
Impact of the HPV Vaccine on Outcomes  
 In vaccine trials, one month after completion of the HPV vaccine three-dose series, 100% 
of women age 15 to 26 years have detectable antibody to each HPV genotype (Cutts et al., 2007). 
Additionally, the antibody levels achieved after vaccination were found to be inversely related to 
age (Cutts et al., 2007). Therefore, the vaccine produces the greatest immune response the earlier 
it is given.  According to Markowitz et al. (2016), within six years of the vaccine introduction in 
the United States there was a 64% decrease in the quadrivalent HPV types in females age 14 to 
19 years old and 34% in females age 20 to 24 years old. 
Literature Review 
 
A literature review for this quality improvement project was conducted using the 
following databases: PubMed, CINAHL, and Google Scholar.  Key words were used in the 
literature search included HPV vaccine, human papillomavirus vaccine, rates, uptake, strategies, 
adherence, barriers, provider recommendation, beliefs, and knowledge.  Additionally, articles 
were evaluated from the reference list of other relevant published articles and systematic reviews 
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as part of the literature review.  Articles in the English language and published within the last 10 
years were used as references. Textbooks were used as supportive material for the theoretical 
framework. Reputable websites such as the CDC were used to gather pertinent information and 
additional resources.  
HPV Vaccination Practice Barriers Among Providers 
There are many reasons why a provider may have barriers for recommending the vaccine 
and these reasons may differ across different organizations and patient populations that are 
served (Holman et al., 2014; Cole et al., 2017; & Vollrath, Thul & Holcombe, 2017). In an 
interview study of providers, they report recommending the vaccine based on perceived risk and 
potential for sexual activity and preferred vaccinating older female children compared to younger 
children (Hughes, Jones, Feemster & Fiks, 2011; Goff et al., 2011). This may be related to the 
vaccine’s negative association with sexual activity and promoting sexual activity, particularly as 
a concern among parents regarding the potential for discussion of sexual activity when 
recommending the vaccine (Cole et al., 2017). Providers also forget to offer the vaccine due to 
time constraints (Holman et al., 2014). In an integrative review of the literature investigating 
methods for increasing HPV vaccine rates, providers that self-reported greater HPV vaccine 
knowledge were more likely to recommend the vaccine (Vollrath, Thul & Holcombe, 2017).  
In a survey of primary care providers, 64% report using a HPV vaccine communication 
tool during visits most of the time (Dempsey, et al., 2016). In a cross-sectional survey measuring 
predictors of provider recommendation for the HPV vaccine, women were over 10 times more 
likely to receive a HPV vaccination recommendation than men (Gerend, Shepherd, Lustria & 
Shepherd, 2016). Also, white participants with health insurance were more likely to report 
receiving recommendation for the vaccine (Gerend et al., 2016). With these findings, the authors 
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concluded that a possibility is that providers have limited time and may be more likely to 
recommending the HPV vaccine to those they perceive to be most accepting (Gerend et al., 
2015). 
HPV Vaccination Barriers Among Patients and Parents 
 
Like provider barriers, there are many factors that may cause barriers for vaccinating for 
HPV among patients and parents (Dorell et al., 2014; Cole et al., 2017; & McBride & Singh, 
2018). Dorell et al. (2014) studied the delay and refusal of the HPV vaccine for girls, which 
revealed that 30% of parents reported having refused or delayed the HPV vaccine for reasons 
that included doubts about safety, effectiveness and if the vaccine is necessary.  Additionally, 
lack of knowledge and understanding of the vaccine has been reported in literature as being a 
primary reason parents do not vaccinate their children (Cole et al., 2017). McBride and Singh 
(2018) reported that men were less likely than women to report having a conversation with a 
provider regarding the HPV infection and vaccine.  There is also very low understanding and 
knowledge of the other non-cervical cancers caused by HPV (McBride & Singh, 2018). This is a 
concern due to the high incidence of non-cervical cancers among men and women, and a higher 
prevalence of oral HPV infection in men (Taylor, Bunge, Bakker, & Castellsague, 2016). The 
belief that only sexually active adolescents should be immunized has also been identified as a 
reason that a parent may want to refuse or delay the vaccination for their child at a younger age 
(Holman et al., 2014). Finally, the vaccine series completion requires multiple return visits and 
may contribute to decreased rates of completion among both males and females.  Studies have 
found that younger patients are more likely to complete the vaccine series than older adolescents 
(Holman et al., 2014).  
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Cost has also been identified as a potential barrier for patients and parents. In general, 
each immunization dose may cost around $130-$150.  However, most health insurances pay for 
the cost of all three doses and the HPV vaccine is included in the Vaccines for Children (VFC) 
program up to the age of 18 years (Association of Reproductive Health Professionals (ARHP), 
n.d.).  
Strategies for Increasing HPV Vaccination 
There are many strategies identified in the literature that may assist in increasing HPV 
vaccination adherence.  These interventions include provider education, patient and family 
education, and automated reminders.  The CDC (2018c) recommends implementing systems, 
such as establishing policies or creating processes to check immunization status at every visit. 
Also, all staff within the practice site should be included when establishing awareness of the 
HPV vaccine’s benefits, so that any clinic personnel feels comfortable answering patient and 
parent questions.  One identified strategy to identify vaccine need via an electronic health record 
included an alert where there was a significant improvement in captured opportunities to receive 
the vaccine for acute visit types (Mayne et al., 2014).  
 Roncancio et al. (2017) found that Hispanic mothers were first introduced to the vaccine 
and would learn about the HPV vaccine in the primary care clinic, which lead them to proceed 
with vaccinating their child.  In another study, parents reported an increase in knowledge of the 
HPV vaccine after utilizing a computer-based learning PowerPoint™ to provide information on 
the vaccine (Ciparino, Scoloveno & Kelly, 2018). These examples support the essential role that 
primary care providers play in clinic to initiate conversations regarding the vaccine.  It is 
important to provide consistent education to all patients and parents who are eligible to receive 
the HPV vaccine.  
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In these education conversations, it is necessary to relieve any concerns regarding 
negative connotations of the HPV vaccine in connection to sexual activity.  In a study of Haitian 
parents and female patients, it was found that provider recommendation styles varied among 
providers, which was contributed as a crucial step leading to the decision for getting the HPV 
vaccine or not (Pierre-Victor, Stephens, Clarke, Gabbidon, & Madhivanan, 2017). When a 
provider framed the vaccine conversation in a way that referenced it as a cervical cancer 
prevention vaccine, this was reported as well-received.  However, when the conversation was 
framed around sexual activity, the vaccine recommendation was poorly received and likely lead 
to missed opportunities (Pierre-Victor et al., 2017). While first identifying patients in need of the 
vaccine is vital, once these patients are identified it is equally imperative that effective 
recommendation techniques are utilized to impact HPV vaccine adherence. 
Project Aims 
 This quality improvement project conducted at a primary care clinic in rural Kansas 
consisted of three aims: (1) to assess system barriers for identifying patients in need of the HPV 
vaccine and providing information for effective recommendation to receive the HPV vaccine; (2) 
use stakeholder input to develop a standardized process for identification and delivery of HPV 
vaccine information; and (3) to improve identification of patients in need of the HPV vaccine 
and decrease missed opportunities. 
Project Questions 
1. What is the current process for identifying patients in need and recommending the 
vaccine? 
2. What are the barriers for identification and recommendation of the vaccine in the patient 
population that is served? 
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3. Does the standardized process for identifying patients in need decrease missed 
opportunities?  
4. Is there an increase in HPV vaccine injections administered at the county health 
department by standardizing the process in the clinic for identification and 
recommendation at every patient visit? 
Theoretical Framework 
Lewin’s change theory model was used as the theoretical framework to guide the project.  
Lewin’s was a behavioral scientist who published work in the 1940s applying social theory to 
group process and action research within the social sciences which was used as a model for 
change among industries in this era (Lewin, 1997).  Lewin described a force field model which 
involves achieving an equilibrium of group dynamics and group decision to influence change 
(Butts & Rich, 2015). Lewin theorized if group decision is involved in the process of change, 
this displays an advantage because if a group member uses an individual procedure this creates a 
driving negative force and acts as a resistance to change (Lewin, 1997). However, if group 
standards are changed this may influence the individual and therefore stabilize or equilibrate the 
individual to work on the new group level (Lewin, 1997). Individuals are often influenced by 
group norms within their environment, therefore change should target group behavior and 
support group decision-making in order to create not only a process change but a culture change 
as well (Batras, Duff, & Smith, 2014). Following the elements of Lewin’s change theory model, 
all clinic staff will play an active role in decision-making for the process change at the clinic in 
order to impact the group dynamic within the clinic environment and impact lasting change.  
Lewin described a three-step model for successful change to achieve higher level of 
group performance and permanency among group standards (Lewin, 1997). These steps include: 
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(a) unfreezing, (b) moving, and (c) refreezing (Lewin, 1997). The “unfreezing” step can involve 
identifying problems or issues, benchmarking, analyzing internal performance, or performance 
barriers (Batras, Duff & Smith, 2014). The next step of “moving” is the process of taking action 
through implementing or trialing a change within a group which may include redesigning roles 
or responsibilities and providing additional training (Batras, Duff & Smith, 2014). The last step 
of ‘refreezing” in the process of redistributing group norms, organizational culture, practices and 
policies to be able to maintain the change (Batras, Duff & Smith, 2014). The three steps in 
Lewin’s model for change were addressed in this project and conceptualized to be used as a 
guide to meet the project aims (see Figure 1.) 
 
Methods 
Setting 
This project was conducted at a privately-owned, rural primary care clinic in rural eastern 
Kansas.  Staff at the clinic include a front desk receptionist, certified nursing assistant, and an 
advanced practice registered nurse.  This clinic is unique because the provider does not 
administer vaccines in the clinic.  Instead, the provider refers patients to the county health 
department to obtain vaccines.  In the case of the HPV vaccine only, the provider can send a 
prescription to the local pharmacy based on the patients’ health insurance status.  Therefore, the 
local health departments and local pharmacy were utilized as resources for vaccine availability 
Figure 1. Process change to improve identification and recommendation practices for 
patients eligible to receive the HPV vaccine series in a primary care clinic using Lewin’s 
model for change. 
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and administration to achieve vaccine uptake.  The clinic sees patients across the lifespan and 
accepts all types of health insurance, including Medicaid and Medicare.  The clinic also offers 
payment plans established for the uninsured. 
Sample 
Male and female patients ages 11 to 26 years old were included in this project.  The 
intervention was provided to all patients within the identified age range for all patient encounters 
including a well child check, physicals, well woman exams, sports physicals, follow-ups, or 
acute/sick visits.  
Design 
Timeline 
The first phase of the project lasted from June to September 2018 and involved creation 
of the project proposal and defense of the proposal.  After obtaining faculty approval to begin the 
project, the project director (PD) submitted IRB approval application and obtained agency 
approval from the clinic management to begin the project. 
The second phase of the project began in October 2018.  The PD held an initial meeting 
at the clinic to assess barriers, current practices for identifying appropriate candidates for 
immunizing, and worked with the clinic team to create a standardized process for identification 
and recommendation.  Next, an educational session to review the process change and determine 
each member’s role in the implementation of the process was conducted.  Prior to the 
intervention period, the PD obtained the pre-intervention data for the number of HPV injections 
administered at the county health department.   
After discussing and coordinating with the clinic staff, the intervention period began and 
lasted for 4 weeks.  The PD visited the clinic the second day of implementation and periodically 
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thereafter to check in with the staff, provide support in the implementation process, and review 
the daily log of eligible patient encounters.  Additionally, the PD kept open communication 
through email and phone for the staff to report any barriers, issues, or concerns.   
The final phase of the project was from January to March of 2019.  This time was 
dedicated to obtaining post-intervention data for HPV injections administered at the county 
health department for data analysis and interpretation and analyzing the project results.  Detailed 
project dates up to the project intervention period can be seen in Figure 2.  
 
Figure 2. Establishing a standardized process to improve identification and recommendation 
practices of patients eligible to receive the HPV vaccine series in a rural primary care clinic 
project dates. 
 
Initial assessment.  This quality improvement project aimed to establish a practice 
change in a primary care setting for improving identification and recommendation for patients 
eligible to receive the HPV vaccine and decrease missed opportunities.  First, the PD conducted 
a face-to face, key informant interview with the clinic staff to identify barriers that are exclusive 
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to the clinic and clinic provider, as well as specific questions related to the patient population 
that is served.  The initial discussion included all clinic staff: a front desk receptionist, a certified 
nursing assistant (CNA), and a nurse practitioner (NP).  The PD had established a trusting 
relationship with each clinic staff member after spending a previous semester there for clinical 
training which helped to foster an open and honest discussion.  Open-ended questions were 
asked to engage staff to participate in the discussion to evaluate current identification and 
recommendation practices. The PD facilitated the interview by utilizing an interview guide (see 
Appendix A) as a script which was created with a focus on common barriers among patients and 
providers identified in literature and previously discussed.  The PD recorded the interview 
electronically as well as took detailed notes.   
Educational session.  The PD conducted an educational in-service using a PowerPoint 
presentation to formally review the HPV vaccine identification and recommendation process 
map created with the input from clinic staff during the initial discussion.  Also, further discussion 
for the roles and responsibilities of clinic staff during the project, and strategies for effective 
recommendation was reviewed.  The process map incorporated the use of the CDC HPV vaccine 
decision tree as a guide (see Appendix B) as well as the CDC conversations tip sheet (see 
Appendix C) to be used as a guide (CDC, 2018a). Therefore, these documents were reviewed 
with staff as well.  Updated HPV vaccine uptake rates for the county, project purpose, cost and 
access specific to the clinic’s patient population, vaccine safety, recommendation strategies, 
HPV vaccine talking points, and additional project details including contact information for the 
PD were also presented.   
The CDC (2018c) recommends that all clinic staff, from the front desk receptionist to the 
primary care provider, should be aware of HPV vaccine’s importance and current 
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recommendations.  All individuals should be prepared to answer patient or parent’s questions in 
order to improve vaccine uptake (CDC, 2018c). All clinic staff were present for the educational 
session which was conducted over a one-hour period.  The implementation of the practice 
change for identifying patients eligible to receive the vaccine and providing recommendation for 
the vaccine was conducted over a 4-week period.   
Data Collection  
 The purpose of the data collection was to evaluate for improvement of identification and 
recommendation of male and female patients age 11 to 26 years old eligible to receive the HPV 
vaccine for all visit types including well child checks, well woman exams, physicals, acute visits, 
and sports physicals.  In addition, pre-intervention and post-intervention data was collected based 
on communication with the nursing director at the county health department to report the number 
of HPV injections given over a 78-day period preceding the clinic practice change start date, 
collected from the Kansas Immunization Registry.  
During the project period, daily tracking occurred on a patient log recorded by the CNA 
or the NP for all encounters with patients between the age of 11-26 years (see Appendix D).  The 
log contained the following information: (a) visit date, (b) patients’ gender, (c) patient’s age, (d) 
type of visit, (e) vaccine status (f) provider recommendation completed, (g) type of referral, and 
(g) vaccine information card received.  There was also a section on the log for each patient 
encounter to include any comments that were pertinent to the specific patient encounter and 
project outcomes, including patient or parent vaccine refusal.  The PD checked in with staff at 
the clinic periodically to review data entry in the daily patient log.  
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Human Subjects Protection 
There is no need for informed consent from the participants because the decision to 
obtain the vaccine is voluntary and recommendation practices are being followed according to 
best practice guidelines.  Personal health information was protected in data collection; only 
pertinent information was obtained and recorded on the data collection log and no patient 
identifiers were used in project data.  In addition, there was no interaction between the project 
director and the patients.  All data collection was conducted at the clinic site and electronically 
through the Kansas Immunization Registry provided by the nursing director at the county health 
department.  The PD obtained a signed letter of support to conduct the project from the clinic 
owner and nurse practitioner at the clinic site which was included in the submission for IRB 
approval.  The PD obtained IRB designation for quality improvement from the University of 
Kansas Medical Center after obtaining faculty approval and prior to starting the project. 
Results 
Initial Assessment 
Themes were identified and evaluated based on participant feedback and group consensus 
from the initial discussion.  An affinity diagram was used to evaluate perceived themes regarding 
barriers in current practice for identifying and recommending the vaccine after completing the 
initial discussion (see Figure 3). These themes from the discussion were interpreted and later 
reviewed with clinic staff during the education session.  
According to the CDC (2018c), a strategy for increasing vaccine uptake is to create a 
standard procedure to follow in order to increase or maintain vaccination rates including 
reviewing vaccination history at every visit.  From the feedback identified in the initial 
discussion, a process map for identifying patients that need the HPV vaccination at every visit 
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was created to establish a standard workflow for identifying eligible patients that is unique to the 
clinic.  An example process map with actions taken by each staff member was introduced at the 
end of the discussion and edited to create the final process map with the clinic staff’s input based 
on their expertise with clinic workflow.  Additionally, in the initial discussion the clinic staff had 
a chance to address barriers to recommending the vaccine as well as the current practice in the 
clinic.  Each staff member were active participants in the discussion and had thoughts and ideas 
to contribute.  
 
 
Access. Barriers to accessing the HPV vaccine was a prominent finding in the initial 
discussion.  When asked about adequate coverage of the HPV vaccine in the population served at 
the clinic, staff reported that there was probably not adequate coverage however reported the 
vaccine is encouraged by the provider especially during well-child checks.  Staff discussed that 
the local county health department where HPV vaccines are available for patients in the vaccine 
-County health 
department not in 
town.
-High cost for non-VFC 
program patients.
-Expensive to keep 
vaccine in the clinic.
-Parental consent is a 
barrier.
-NP discusses 
vaccine status with 
patients. 
-No other staff 
discuss vaccine 
status at patient 
visits. 
-Concern for 
vaccine safety. 
-Belief that child is 
not at risk.
-No discussion during 
acute/sick visits. 
-Discuss vaccines at the 
end of visit.
-Present as not an 
optional vaccine. 
-Different approach for 
child vs. teenager. 
-Recommend to girls 
more often. 
Access Communication PracticeKnowledge
Figure 3. Affinity diagram to evaluate perceived themes and subgroups regarding barriers 
and current practice for identifying and recommending the vaccine after completing the initial 
discussion. 
 
  21 
   
for children (VFC) program was approximately 7 miles from town which might be too far of a 
distance for some people.  Additionally, the high cost of the vaccine for non-VFC program 
patients or uninsured patients was also identified as a potential barrier.  The clinic NP discussed 
that she felt it was expensive to keep the vaccine in the clinic.  Another staff member discussed 
that she was concerned about parental consent as a barrier.  This staff member brought up the 
concern that some adolescents might be hesitant to ask their parent about the HPV vaccine in 
fear that their parent might think they are sexually active.  
Communication. During the initial discussion the staff talked through their current 
process.  The front desk receptionist and certified nurse assistant did not have an active role 
identifying or screening patients in need of the vaccine or recommending vaccines to patients.  
The NP would be the primary person to discuss vaccine status with a patient or parent.  
Knowledge. Barriers to knowledge discussed by the clinic staff included lack of general 
public knowledge regarding the safety of the vaccine which is sometimes pre-determined by 
patients or parents.  Additionally, the parental belief that children aren’t at risk, especially 
younger children, was brought up as a knowledge gap among the patient population served at the 
clinic.  
Practice. The NP provided most of the information for current practice as she was the 
primary person involved in identifying patients in need of the vaccine and providing the 
recommendation.  The NP discussed that her current practice for recommending is consistent for 
physicals and well child checks and typically discussion of vaccine status occurs towards the end 
of a visit.  The NP reported that she typically would not discuss vaccine status during a sick or 
acute visit.  The NP felt that she may have a different approach in recommending for a child vs. 
an adolescent and felt she recommended to girls more often. An example was that for a younger 
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child the conversation might be around the vaccine protecting against a virus and for an older 
patient the conversation might be that the vaccine helps protect against a sexually transmitted 
disease.  The NP further discussed that a recommendation strategy currently used in her practice 
was to present the HPV vaccine as a vaccine that is not an optional one.  If the patient is wanting 
the vaccine, they are given a patient education handout and referred to the county health 
department or a prescription is sent to the local pharmacy. 
Implementation of the Practice Change 
The final process map (see Figure 4) was created with the help of clinic staff. It began 
with the front desk receptionist flagging all eligible patients visits.  The front desk receptionist 
would then print the patient’s encounter sheet on a pink piece of paper if the patient was eligible 
to receive the vaccine (between the ages of 11-26 years old) for all clinic visit types.  This 
encounter sheet would then be handed off to the CNA that rooms the patient. For verification of 
vaccine status, it was recommended to the CNA to utilize the CDC HPV vaccine decision tree to 
provide additional information when rooming the patient. The CNA would then notify the 
provider of their status and need for vaccination when presenting the patient’s vital signs and 
chief complaint.  Additionally, it was recommended for the NP to utilize the techniques reviewed 
in the educational session as well as from the CDC’s “Tips and Timesavers for Talking with 
Parents” to facilitate a conversation with the patient or parent as part of the patient’s plan of care 
(CDC, 2018a). If it was established that the patient needed the HPV vaccine, the provider would 
recommend the vaccine and appropriate dose series.  Depending on the patient’s insurance 
status, the NP would send a prescription to the local pharmacy which was in close proximity to 
the clinic or would refer the patient to the county health department for vaccine administration.  
The NP would then provide the patient with the vaccine information card as well as HPV vaccine 
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patient education that the NP agreed to use.  The vaccine information card was also created with 
the input from staff during the initial discussion and included the number of doses depending on 
the patients age as well as frequency of doses.  On the back of the vaccine information card was 
contact information for the county health department and the local pharmacy.  The NP would 
circle whichever option the patient was referred to for the vaccine. After each eligible patient 
encounter, the CNA or the NP recorded the patient visit in the daily patient log.  
 
 
Data Analysis 
There were 44 patients that visited the clinic during the 4-week project period that were 
identified as age-eligible to receive the HPV vaccine and recommendation provided, if 
appropriate.  Descriptive statistics were used for data analysis to show the percentage of patients 
identified to need the HPV vaccine out of the total patient encounters between the ages 11-26 
years during the project period stratified by age, gender, and type of visit (see Table 1).  
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Figure 4. Clinic process map for identifying patients eligible to receive the vaccine and 
providing recommendation for the vaccine. 
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The type of visit was separated into acute/sick visit, well child checks, physical exam, 
adolescent sport physicals, and miscellaneous follow-ups.  The miscellaneous follow-up visits 
included patient visits to the clinic for follow ups on blood pressure, diabetes, emergency room 
visits, or visits for medication refills.  Overall, 20.5% of patients reported completion of the HPV 
vaccine series.  Additionally, 18.2% of the age-eligible patients were referred to the health 
department and 31.8% had a prescription for the HPV vaccine sent to the local pharmacy that 
carried it.  This was indicated in the process map based on if the patient had insurance or not, as 
the health department provides vaccinations for patients that are part of the VFC program.  
Finally, 20.5% of patients refused or reported to the provider that they wanted to read about the 
vaccine more and review the educational information she had provided to them before sending 
the prescription to the pharmacy or deciding to obtain the vaccine.  The age range for those 
patients or parents of patients that refused or wanted more time to decide were 11-16 years old.  
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Finally, two age-eligible patients were uninsured and did not receive any kind of referral. One of 
these patients was beyond the range to be covered under the VFC program and for other patient 
the reason for no referral was not documented in the comments section of the log. However, 
recommendation was provided to these patients as well as the HPV vaccine information card.  
The number of post-intervention HPV vaccine injections administered over a 78-day 
period following the clinic practice change was compared to the pre-intervention data.  There 
was no improvement in the amount of HPV vaccines administered at the county health 
department as there were 18 total vaccine administrations pre-intervention, and only 9 total 
vaccine administrations post-intervention.  Additionally, because no patient identifiers were used 
in data analysis, it was not possible to differentiate if the same patient received the first dose and 
then a subsequent second or third dose to complete the series during the pre and post-
intervention timeframes (see Figure 5).
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Figure 5. Human Papillomavirus 9-valent vaccine administrations provided to patients eligible for 
the vaccine for children (VFC) program at the county health department, organized by age range 
and dose. The pre-intervention data time period was from August 1, 2018 to October 22, 2018. 
The project intervention began at the clinic on October 25, 2018 and ended on November 21, 
2018. The post-intervention data time period was from October 25, 2018 to January 10, 2019.  
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Discussion 
Utilizing resources and training to educate and prepare providers to consistently 
recommend the vaccine can increase HPV vaccine uptake (Cole et al., 2017). This quality 
improvement project aimed to standardize vaccine identification processes and recommendation 
practices.  This was done by creating a process map to identify patients eligible to receive the 
vaccine during every patient visit and educating on recommendation practices to all clinic staff 
members.  Although provider recommendation has clearly been identified as a way to increase 
HPV vaccine uptake, this recommendation is something that should be provided during every 
patient visit, and not just well-child checks.  It is plausible that identification and 
recommendation should go hand-in-hand as an approach to increase HPV vaccine uptake and 
decrease missed opportunities.  The effectiveness of the intervention was evaluated by analyzing 
the number of patients identified as being eligible to receive the vaccine during the project period 
for every visit type. 
During the planning of this quality improvement project it was communicated by the 
owner of the clinic, the NP, to the PD and the project committee chair that closure of the clinic 
site was imminent.  It was decided by the PD and the project committee chair to push the project 
timeline ahead of schedule so that the project could be completed.  It was not possible to provide 
a final discussion with clinic staff or disseminate the findings to the clinic staff after the project 
was complete as the post-intervention data had not yet been collected by the time the clinic 
closed on January 11, 2019.   
The project results yielded a 4-fold increase in identification and recommendation for 
acute/sick visits compared to well-child check visits as 65.9% of eligible patients that visited the 
clinic for acute or sick visits during the project period were identified as needing the vaccine and 
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recommendation was provided as well as a prescription sent or referral to the health department. 
These patient encounters would have otherwise been missed opportunities prior to the clinic 
practice change.  This result, as well as the results from Wong et al. (2013) which showed high 
rates of missed opportunities for sick or non-preventive types of visits, provides evidence that all 
patient encounters should be viewed as opportunities to provide vaccine recommendation and 
education for age-eligible patients.  This opportunity does not only pertain to the HPV vaccine, 
but other optional vaccines, such as the flu vaccine and the meningococcal B vaccine.  
Although HPV vaccine administration rates were not impacted by this quality 
improvement project, four times more patients were provided recommendation during acute 
visits as compared to well-child check visits.  Also, this project helped to address gaps in 
parental and patient knowledge concerning safety, effectiveness, and necessity for the HPV 
vaccine that is described in the literature and was identified in the initial discussion from clinic 
staff as a barrier to increasing rates of HPV vaccination. Studies by Roncancio et al. (2017) and 
Ciparino, Scloveno, and Kelly (2018) showed initial conversations and education in the primary 
care clinic would lead to proceeding with obtaining the HPV vaccine and an increase knowledge 
of the vaccine when parents were introduced to the HPV vaccine in the primary care clinic.  
During the project period it was documented that 20.5% of the patient encounters were provided 
recommendation and educational material as the parent wanted to learn more about the vaccine.  
With the recommendation and education alone, this might have piqued the parents’ interest in 
learning more about the vaccine, which would not have happened had they not received the 
initial recommendation in the primary care clinic.   
The results for male and female identification and recommendation were comparable to 
other studies that show that men are less likely to be provided recommendation for the HPV 
  28 
   
vaccine than women (Gerend et al., 2016). The results revealed 38.6% of age-eligible patients 
identified and recommendation provided were males and 61.4% were females.  
Strengths and Limitations  
Current process and barriers were discussed and evaluated during the initial discussion 
and aided in creating the clinic process map for identifying and recommending the HPV vaccine. 
The standardized process did decrease missed opportunities for identification and provider 
recommendation where a referral was provided for acute or sick visits.  Unfortunately, there was 
no increase in HPV vaccine injections administered at the county health department.   
The number of vaccines administered at the pharmacy was not captured.  However, it was 
reported out to the PD at one of the clinic check-ins during the project period that the other local 
pharmacy had reached out to the clinic NP and was also going to start carrying the HPV vaccine. 
This was a strength outside of the intended project results, as insured patients were now able to 
get the choice of which pharmacy they preferred to have their prescription sent to.  Thus, 
increased access to vaccines for patients in the community was realized.  The PD had completed 
a previous clinical experience in this clinic which served as another project strength.  The 
relationship developed beforehand between the PD and the clinic helped to gain buy-in from the 
staff, thus impacting the willingness to adopt the clinic practice change.  
A limitation to this project, after reflecting on these results, might have been related to 
the timeframe for the pre and post- intervention data.  The pre-intervention data included vaccine 
injections administered starting in the month of August, which is possible that this is a time when 
the health department sees a higher influx of patients needing updated on vaccines due to school 
starting.  Also, the county health department only provided the HPV vaccine to VFC’s eligible 
patients.   
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A primary limitation to not having an impact on vaccine administration rates is that the 
primary care clinic in which the project was completed did not provide and administer the HPV 
vaccine.  Therefore, after identifying and recommending the vaccine it was still up to the patient 
or parent to follow-through with obtaining the vaccine once leaving the clinic.  Other project 
limitations included the inability to verify that all patients age 11-26 seen in clinic during the 
project period were logged as being identified and recommendation provided. This was because 
as part of the project the plan, the PD did not have access to the electronic health record, patient 
encounter lists, or any kind of patient identifiers.  
A final limitation for this quality improvement project could have been attributed to the 
impending closure of this clinic. Although the project intervention period did not need to be 
shortened, it is plausible to conclude that there might have been outside stressors and distractions 
for staff when implementing the practice change.  Additionally, this development during the 
project might shed light on the barriers that primary care providers face in rural communities in 
regard to access to care for their patients as well as financial and practice resources.  
Implications for Future Practice 
One strategy identified in the literature to provide significant increases in capturing 
opportunities to receive the vaccine for acute type of visits is electronic health record alerts 
(Mayne et al., 2014). Due to time constraints for clinic providers, this strategy might be more 
effective and impactful in the project clinic.  For this practice change, all patients were asked for 
their vaccine status if chart was not up-to-date or checked prior to the visit.  By having an alert in 
the electronic medical record that was filtered to age eligible patients and counted for a 
documented vaccine series completion in the electronic chart, this would defer the need to have a 
discussion with patients that have already completed the vaccine series.  Also, it would help to 
  30 
   
decrease communication barriers between clinic staff.  The clinic did use electronic medical 
record and charting system so this was discussed as a possibility for future state.  Other studies 
and quality improvement projects should be conducted within small, rural clinics to create 
standardized processes utilizing recommendation tools, as well as using every patient encounter 
as an opportunity to identify need and provide recommendation.  These standardized processes 
should focus on adapting to specific workflow within clinics, staff, and resources available while 
including all clinic staff members in the process to assist in improving HPV vaccination rates as 
well as public knowledge.  
Dissemination of project results to clinic staff was not possible due to the closure of the 
clinic.  However, the PD did communicate via email with the clinic NP for project follow-up 
questions.  The questions that were asked were as follows: 1. What barriers, if any, did you find 
when implementing the intervention for identifying and recommending the HPV vaccine for 
every patient visit age 11-26 years old? 2. What do you feel went well with the process map for 
identifying and recommending the HPV vaccine for all patient visits at your clinic? 3. Would 
there be anything that you would change with the process going forward? The clinic NP stated “I 
felt the biggest barrier was preconceived ideas about vaccines that the parents had. They already 
had their mind made up about vaccines before even hearing about it” (personal communication, 
January 7, 2019). Additionally, the clinic NP felt that the practice change was not difficult once 
all the staff got into a routine with it. Based on this feedback, it is plausible that extending the 
project period beyond 4 weeks might have yielded more patients being identified, as the clinic 
staff may needed more time to acclimate to the practice change.  Finally, the NP stated that 
changes she would make after trialing the practice change in the clinic would be to make the 
HPV vaccine education with the patient more of the clinic nurses’ responsibility at check-in.  
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Future research should focus on looking at perceptions of adolescents’ receiving parental 
consent for the HPV vaccine and how this might impact vaccine rates.  This topic was brought 
up as a barrier from clinic staff during the initial discussion.  Also, the findings showed that 
patients or parents were hesitant to move forward with obtaining the vaccine after 
recommendation and receiving patient education.  Therefore, future research should also 
consider strategies to effectively address hesitancy from parents and patients.  Finally, additional 
studies looking at framing conversations to ensure clear, consistent messaging in regard to 
recommendations from providers. 
Future practice improvement looking at developing team-based approaches or 
standardized processes to screen and educate patients on the HPV vaccine at every patient visit is 
imperative.  Rural area practices should also consider gaining better partnership with county 
health departments to make improvements on vaccine rates.  Finally, providing programs, 
information, and resources for the HPV vaccine to be more accessible for privately-owned 
clinics, especially those in rural areas, is of crucial benefit to support the public health of 
communities such as this one.   
Conclusion 
The three aims of this project were met as system barriers were assessed and stakeholder 
input was utilized to create a standardized process for identifying age-eligible patients and 
recommending the HPV vaccine in a rural primary care clinic.  Additionally, the third aim of this 
project was met as the results showed that missed opportunities were decreased by implementing 
the standardized process of identifying need and recommending for every patient visit type.  
Although standardizing the process for identifying patients in need did decrease missed 
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opportunities, there was not an increase in vaccine administrations at the county health 
department. 
 The results of this project support the notion that creating standardized processes within 
organizations large and small is an effective way to improve health and quality of care.  In 
addition, standardized processes can be effective to potentially improve vaccine uptake by 
screening patients eligible for the vaccine at every patient visit, not just during a well woman or 
well-child check.  However, clinics need to have the ability to administer the vaccine to have 
optimal impact on vaccine uptake.  
This project displayed what is consistent in research; acute and sick visit types in primary 
care clinics present as missed opportunities for identifying patients in need for the HPV vaccine 
and providing recommendation.  Creating a standardized process for clinics to identify, screen, 
and recommend the HPV vaccine in an efficient and effective way to help decrease missed 
opportunities, initiate provider to patient vaccine related conversations, improve knowledge gaps 
within rural communities, improve HPV vaccination rates, and make reducing HPV related 
diseases for future generations a priority.  
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Appendix A 
 
Initial Discussion Interview Script 
 
1) Do you feel there is adequate coverage of the HPV vaccine among the patient population 
that you serve? 
2) Do you feel there is adequate knowledge of the HPV vaccine among the patient 
population that you serve?  
3) Do you feel there are barriers to accessing the HPV vaccine in the patient population that 
you serve?  
4) Do you feel there is a consistent practice in the clinic for identifying patients that are age-
eligible and in need of the vaccine? 
5) What are the current responsibilities for each clinic staff member in checking a patient’s 
HPV vaccine status? 
6) Is it common in your practice to recommend the HPV vaccine at every patient visit for 
age-eligible patients? 
7) What is your current recommendation style for the HPV vaccine?  
8) Does your recommendation style change based on the type of patient visit and/or patient 
characteristics? 
9) From your perspective, what are common reasons why you may not recommend the 
vaccine, if any? 
10) From your perspective, what are common reasons why a parent/patient may not want the 
vaccine?  
11) Do you feel there are certain age groups, genders, social and/or ethnic groups that may 
contribute to recommending the vaccine more often or less often? 
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Preventing Cancer Just Got Easier
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Appendix B 
 
HPV Vaccine Decision Tree  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. Retrieved from “Human Papillomavirus (HPV): Clinical Factsheets and Guidance” by the 
Center for Disease Control (CDC), 2017 at https://www.cdc.gov/hpv/hcp/clinician-
factsheet.html. 
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Appendix C 
 
CDC Talking to Parents About HPV Vaccine Handout 
 
 
Note. Retrieved from “Human Papillomavirus (HPV): Clinical Factsheets and Guidance” by the 
Center for Disease Control (CDC), 2017 at https://www.cdc.gov/hpv/hcp/clinician-
factsheet.html. 
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Appendix D 
 
HPV Vaccine Screening and Recommendation Log 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
